Kiniksa Pharmaceuticals International, plc (KNSA)
$78.53-0.90%Close
BUYBULL · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5.9B
- Beta
- 0.09
- P/E (TTM)
- 73.39
- Short % float
- 5.26%
- Days to cover
- 6.4
- SI change
- -2.5%
- 1W
- +1.87%
- 1M
- +2.55%
- vs SPY 1W
- +2.01%
- vs SPY 1M
- +0.04%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$6.9BCRISISQ 9$79.90-6.34%
- IMVTSELLImmunovant, Inc.$6.2BCRISISQ 25$30.26-2.61%
- ORKASELLOruka Therapeutics, Inc.$4.7BCRISISQ -3$77.28-2.69%
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.43-4.89%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.21-0.14%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$46.21-0.98%
- AVTXSELLAvalo Therapeutics, Inc.$706MCRISISQ -10$13.43-9.29%
- PHARSELLPharming Group N.V.$675MCRISISQ -1$9.53-1.77%
- ACRSSELLAclaris Therapeutics, Inc.$529MCRISISQ 9$3.79-3.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 62
- VALUE
- 25
- GROWTH
- 49
- GARP
- 72
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC8.2%
REV YoY-
ROE13.7%
EPS YoY-
ROA9.0%
GROSS54
OP12
NET10
[VALUATION]
P/E TTM73.39
P/E FWD43.32
SECTOR PE20.34
INDUSTRY PE104.65
P/B9.31
P/FCF-
EV/EBITDA51.90
EV/EBIT-
PEG0.96
FCF YIELD-
RISK
INT COV-
D/E1.36
ALTMAN Z-
CURR RATIO3.90
ND/EBITDA-
BETA0.09
Company news
FAQ
- What is LOPJLB’s current signal on KNSA?
- LOPJLB’s latest quantitative signal on Kiniksa Pharmaceuticals International, plc (KNSA) is BUY in a BULL regime. Signals are updated daily.
- What market regime is KNSA in?
- Kiniksa Pharmaceuticals International, plc (KNSA) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Kiniksa Pharmaceuticals International, plc (KNSA) do?
- Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL…